More likely in my mind to be a partnership and further funds injection from that type of transaction.
While I think we're extremely busy conducting/cooperating on these 7 Clinical trials for paxalisib and finalising the Cantrixil phase 1 Clinical trial data, it may also be that we are going to venture on another molecule, perhaps a far larger commercial and impactful medical need!!?
@rikki you may want to add your own thoughts against your good question. When I heard that I was truly impressed on the level of confidence JG projected! I had been thinking that Kazia would not just become a company that's bought out to end up as another entity, hence my question to him recently on taking a partnering level commercial agreement for paxalisib for the future...
So many chances of success now across many forms of cancer for only 2 molecules under our guidance. I think and hope we will do another GDC-0084 in the near future.
KZA Price at posting:
82.0¢ Sentiment: Buy Disclosure: Held
